Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
von mehreren Autoren
4 von 6 Insights
Licensing out: Try not to get benched
von Colin McCall und Justyna Ostrowska
COVID-19: Vertrieb von Schutzmasken – Ende der Sonderzulassungs-Praxis des BfArM
IP: Licensing and insolvency
von mehreren Autoren
UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
von Paolo Palmigiano
6 von 6 Insights
Arbitration for life sciences companies
von mehreren Autoren
Legal advice privilege: where are we now?
von Georgina Jones
Brexit and MDR readiness for overseas medical devices manufacturers: where should you locate your sales operations in Europe?
von Alison Dennis
Territorial licensing: "start at the end before you begin"
von Colin McCall und Justyna Ostrowska
A missed chance
von Dr. Anja Lunze, LL.M. und Verena Bertram
Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
An exploration of patent pools, R&D and current initiatives.
von Dr. Anja Lunze, LL.M. und Dr. Jan Phillip Rektorschek
2 von 6 Insights